IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression - Takeaways - MDSpire

IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression

  • By

  • Alexandre Pérez-González

  • Jacobo Alonso-Domínguez

  • Inés Martínez-Barros

  • Aida López-López

  • Laura Labajo-Leal

  • Antonio Ocampo

  • Eva Poveda

  • May 28, 2026

  • 0 min

Share

  • 1

    A prospective cohort study included 35 virologically suppressed people with HIV who switched from a three-drug regimen to a dolutegravir-based two-drug regimen.

  • 2

    At 12 months, plasma concentrations of MIG and IL-18 increased significantly, while IL-6 and IP-10 levels remained stable.

  • 3

    No virological failure or transient low-level viremia episodes were observed during the study period.

  • 4

    The increase in IL-18 concentrations was not correlated with changes in IL-18BP, suggesting alternative regulatory pathways.

  • 5

    The study highlights persistent low-grade inflammation in virologically suppressed individuals despite effective antiretroviral therapy.

Original Source(s)

IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression

  • by Alexandre Pérez-González, Jacobo Alonso-Domínguez, Inés Martínez-Barros, Aida López-López, Laura Labajo-Leal, Antonio Ocampo, Eva Poveda

  • May 28, 2026

Related Content

Assessing the association of physical distancing to avoid COVID-19 with health-related quality of life in immunocompromised adolescents: results from the cross-sectional observational EAGLE study

Correction: Channel selection of metagenomic next-generation sequencing in infants pathogen detection: a multicenter cross-sectional study

Which vaccines will curb the Ebola outbreak? WHO debates